

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited
新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

MAJOR DISPOSAL –
DISPOSAL OF 25% OF THE ISSUED SHARE CAPITAL OF
THE TARGET COMPANY:
DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of New Ray Medicine International Holding Limited (the “**Company**”) dated 29 March 2022 (“**Announcement**”) in relation to, among other things, the entering into of the Disposal Agreement. Unless the context requires otherwise, capitalised terms used herein shall bear the same meanings as defined in the Announcement.

As stated in the Announcement, a circular (“**Circular**”) containing, among other things, further information on the Disposal, the Disposal Agreement and the transactions contemplated thereunder and other information as required under the Listing Rules together with a notice of the SGM and a form of proxy will be despatched to the Shareholders on or before 16 May 2022.

As additional time is required for the Company to finalise certain information of the Group to be included in the Circular, the expected date of despatch of the Circular will be postponed to a date falling on or before 17 June 2022.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 13 May 2022

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.